CPHARM - CRC Study
Community Pharmacy-Based Health-Seeking Behaviour and Colorectal Cancer Screening Uptake Among Malaysian Adults
Colorectal cancer is one of the most common cancers in Malaysia and worldwide. Although it can often be prevented or treated successfully when detected early, many people in Malaysia are diagnosed at an advanced stage. Screening tests, such as the immunochemical faecal occult blood test (iFOBT), can help detect early signs of colorectal cancer; however, participation in screening remains low.
Community pharmacies are easily accessible healthcare settings where people frequently seek health advice. Pharmacists may play an important role in improving awareness and encouraging colorectal cancer screening by providing education and support. However, more information is needed to understand how people perceive and respond to pharmacy-based colorectal cancer screening.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Yen Jun Wong
- Numéro de téléphone: 60355146286
- E-mail: yenjun.wong@monash.edu
Sauvegarde des contacts de l'étude
- Nom: Chee Tao Chang
- E-mail: davidcct.crc@gmail.com
Lieux d'étude
-
-
Selangor
-
Klang, Selangor, Malaisie, 41050
- Big Caring Group
-
Contact:
- Shiau Hueh Yeow
- Numéro de téléphone: 60374531988
- E-mail: shiauhueh.yeow@bigcaring.com.my
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Adults aged 50 to 75 years
- Visiting participating community pharmacies during the study period
- Able to provide informed consent
- Willing to complete the study questionnaire
- Willing to provide consent for follow-up assessment of: iFOBT provision, iFOBT testing completion, iFOBT results
Exclusion Criteria:
- Previous diagnosis of colorectal cancer
- History of colonoscopy within the recommended screening interval (within past 1 year)
- Currently experiencing symptoms suggestive of colorectal cancer
- Having a first-degree relative diagnosed with colorectal cancer
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Pharmacy customers with campaign
Campaign Components The one-day Ribbon of Hope campaign will be implemented at each intervention pharmacy to promote colorectal cancer awareness and screening uptake.
The campaign consists of educational materials and one-on-one education about colorectal cancer.
|
Campaign Components The one-day Ribbon of Hope campaign will be implemented at each intervention pharmacy to promote colorectal cancer awareness and screening uptake.
The campaign consists of educational materials and one-on-one education about colorectal cancer.
|
|
Aucune intervention: Pharmacy customers without campaign
Customers will receive standard pharmacy services such as medication dispensing and general health advice, but no educational materials or one-on-one education on CRC will be provided.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Beliefs and perceptions toward colorectal cancer and iFOBT screening
Délai: From enrollment to the 8th week follow-up.
|
Beliefs and perceptions toward colorectal cancer and iFOBT screening, measured using the Champion Health Belief Model Scale - Colorectal Cancer - Malay (CHBMS-CRC-M) subscales of perceived susceptibility, perceived benefits, and perceived barriers, between customers from pharmacies with and without the one-day awareness campaign. Each item is rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree). Domain scores will be calculated by summing (or averaging) the items within each domain, with higher scores indicating greater perceived susceptibility, benefits or barriers. |
From enrollment to the 8th week follow-up.
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Proportion of participants who were willing to accept and perform iFOBT, report iFOBT results, and follow-up if needed.
Délai: From enrollment to the 8th week of follow-up
|
From enrollment to the 8th week of follow-up
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 53176
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .